


Mauritania

\$1,100

Region: West Africa

Key information on co-financing

- Gross National Income per capita (2017):
- Co-financing status (2019): Preparatory transition phase
- Country is projected to stay in preparatory transition phase for next 5 years



Immunisation financing


	2013	2014	2015	2016	2017	
Vaccines used in routine immunisation						
 Government expenditure 	\$ 365,610 \$	518,833 \$	776,764 \$	601,825 \$	550,325	
- Total expenditure	\$ 2,235,017 \$	3,177,891 \$	13,471,336 \$	5,027,085 \$	2,726,825	
- Government as % of total	16%	16%	6%	12%	20%	
Routine immunisation						
 Government expenditure 	\$ 412,277 \$	3,556,218 \$	836,146 \$	1,089,278 \$	1,857,831	
 Total expenditure 	\$ 4,352,386 \$	5,823,981 \$	5,012,639 \$	5,514,538 \$	4,034,331	
- Government as % of total	9%	61%	17%	20%	46%	

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product:

0.3%

Source: WHO National Health Accounts, 2015



required

Expenditure on routine

Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing
HepB mono	Routine	2005-2008	No
Pentavalent	Routine	2009-present	Yes
PCV	Routine	2013-present	Yes
Rotavirus	Routine	2014-present	Yes
Meningitis A	Campaign	2014	No
IPV	Routine	2015-present	No
MR	Campaign	2018	No
MR	Routine	2018-present	Yes


Co-financing payments

		amount paid by the country	Co-fina	nced vaccines			
2009	\$	97,000	Penta	_	_		
2010	I	98,000	Penta	-	-		
2011	1 '	72,000	Penta	-	-		
2012	\$	120,000	Penta	-	-		
2013	\$	125,000	Penta	-	PCV		
2014	\$	236,000	Penta	Rota	PCV		
2015	\$	519,000	Penta	Rota	PCV		
2016	\$	309,000	Penta	Rota	PCV		
2017	\$	200,000	Penta	Rota	PCV		
2018	\$	316,000	Penta	Rota	PCV	MR	

Co-financing obligations for 2019

	Co-financing obligations		Co-financing obligations	
	(in US\$)		(in doses)	
Rota	\$	83,500		36,000
PCV	\$	169,500		55,800
Pentavalent	\$	34,500		45,500
HPV	\$	21,000		4,500
MR	\$	56,500		80,900
Total	\$	365,000		

Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
HPV national	\$ 5,266	\$ 61,942	\$ 70,235	\$ 40,889	\$ 48,384
MenA Routine	\$ 14,889	\$ 31,117	\$ 36,536	\$ 41,623	\$ 48,537
Penta	\$ 45,493	\$ 53,634	\$ 62,892	\$ 73,212	\$ 85,373
PCV	\$ 194,557	\$ 229,265	\$ 268,802	\$ 313,041	\$ 364,923
Rota	\$ 95,633	\$ 111,935	\$ 130,579	\$ 152,263	\$ 177,501
MR routine	\$ 67,759	\$ 78,471	\$ 91,505	\$ 106,319	\$ 122,390
Total	\$ 423,595	\$ 566,364	\$ 660,548	\$ 727,348	\$ 847,109

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.